Trevi Therapeutics
TRVI
198 hedge funds and large institutions have $1.61B invested in Trevi Therapeutics in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 65 increasing their positions, 62 reducing their positions, and 24 closing their positions.
96% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $5.67M
71% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 24
8% more funds holding
Funds holding: 184 → 198 (+14)
3.45% more ownership
Funds ownership: 101.65% → 105.09% (+3.4%)
5% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 62
0% more funds holding in top 10
Funds holding in top 10: 9 → 9 (0)
1% less capital invested
Capital invested by funds: $1.63B → $1.61B (-$17M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$24.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$20M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11.7M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$9.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$14.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.5M |
| 3 |
O
OrbiMed
New York
|
-$8.24M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$6.88M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$6.78M |
TRVI Hedge Fund Activity: Q1 2026 in Review
198 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q1 2026, worth a combined $1.61B — down 1% from $1.63B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new TRVI positions and 24 closed out — a net gain of 17 holders — while 65 added to existing stakes and 62 trimmed.
The largest buyer was Vestal Point Capital, opening a new position worth an estimated $24.3M. The largest seller was Octagon Capital Advisors, cutting an estimated $14.9M.
- 198 institutional investors held Trevi Therapeutics (TRVI) as of Q1 2026, up from 184 in Q4 2025.
- Funds reported $1.61B of Trevi Therapeutics stock for Q1 2026, down 1% quarter-over-quarter.
- 41 funds opened new Trevi Therapeutics positions in Q1 2026 and 24 closed out, a net change of +17 holders.
- The largest Trevi Therapeutics buyer in Q1 2026 was Vestal Point Capital, an estimated $24.3M added.
- The largest Trevi Therapeutics seller in Q1 2026 was Octagon Capital Advisors, an estimated $14.9M sold.
Based on aggregated 13F filings for Q1 2026.